Global Health Partnerships

Novartis signs new initial agreement with BioNTech to support fill and finish of the mRNA Pfizer-BioNTech COVID-19 vaccine

Basel, October 21, 2021 — Novartis announced today that it has signed an initial agreement to leverage its manufacturing capacity and capabilities to address the COVID-19 pandemic by expanding its support of the fill and finish of the Pfizer-BioNTech COVID-19 vaccine. Novartis will use its sterile manufacturing facilities at its Novartis Technical…

Global Health PartnershipsDisease AwarenessAccess to Healthcare
Novartis and Hewlett Packard Enterprise join forces to advance Novartis global health efforts

Basel, June 23, 2021 — Novartis and Hewlett Packard Enterprise (HPE) today announced a collaboration that aims to accelerate the use of data and digital technologies within Novartis efforts to reimagine global health and improve access to healthcare and medicines.

Novartis AccessGlobal Health PartnershipsFuture of HealthcareAccess to Healthcare
Novartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and other leading organizations to co-create effective, measurable solutions for health equity

Basel, July 20, 2021 — Novartis and the Novartis US Foundation today announced a planned 10-year collaboration with Coursera, the National Medical Association, Thurgood Marshall College Fund, Morehouse School of Medicine and 26 additional Historically Black Colleges, Universities and Medical Schools (HBCUs) to co-create programs that address the…

Social CommitmentGlobal Health PartnershipsFuture of HealthcareEthical Business
Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19

Basel, October 28, 2020 — Novartis and Molecular Partners AG today announced a collaboration in the form of an option and license agreement to develop, manufacture and commercialize Molecular Partners’ anti-COVID-19 DARPin® program, consisting of two therapeutic candidates, MP0420 and MP0423. The collaboration aims to leverage Molecular Partners’…

Reimagine MedicineInfectious DiseasesGlobal Health PartnershipsBiomedical Research
Novartis and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasis

Basel, February 25, 2020 – Novartis and the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development (R&D) organization, have signed a collaboration and licence agreement to jointly develop LXE408, as a potential new oral treatment for visceral leishmaniasis, one of the world’s leading parasitic killers.

Global Health PartnershipsAfricaAccess to Healthcare
Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program

Basel, April 2, 2020 — Novartis today announced plans to initiate a Phase III clinical trial in collaboration with Incyte to evaluate the use of Jakavi® (ruxolitinib) for treatment of a type of severe immune overreaction called cytokine storm that can lead to life-threatening respiratory complications in patients with COVID-191-3.

Social CommitmentInfectious DiseasesGlobal Health Partnerships
Access to Healthcare

Partnering for improved cancer care around the globe

Novartis works tirelessly with third-party organizations to improve access to cancer care.

Access to HealthcareAfricaGlobal Health PartnershipsNovartis Social BusinessOncology
Access to Healthcare

New drugs could offer hope for malaria patients

In a medical treatment facility on the Thai-Burmese border, 21 patients infected with malaria recently participated in a clinical trial.

Disease EradicationGlobal Health PartnershipsMalariaNovartis Social BusinessPatient EducationTropical Diseases
Access to Healthcare

Making healthcare sustainable in the developing world

Today, many companies are trying to solve global health challenges through philanthropy. However, it has become clear that philanthropy alone is no longer enough to make a lasting impact.

Access to HealthcareFuture of HealthcareGlobal Health PartnershipsNovartis Social BusinessSustainable Development
Patient Perspectives

Conversations with Patient Advocates: Ron Hollander, president of INCA

Ron Hollander, president of the International Neuroendocrine Cancer Alliance, talks to us about patient advocacy.

CancerDisease AwarenessGlobal Health PartnershipsOncologyPatient Voices
Access to Healthcare

Women in Science: Fionnuala Doyle

Doyle describes the road to improving patient outcomes across Europe through the HARMONY Alliance.

CancerDigitalGlobal Health PartnershipsOncologyWomen in ScienceWorking at Novartis
Access to Healthcare

Living with hypertension in Cameroon on a few dollars per day

In Cameroon, seeking treatment for chronic diseases can be a long journey.

Access to HealthcareAfricaGlobal Health PartnershipsNovartis AccessNovartis Social Business